Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 __ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Mark McClung - Chief Operating Officer Conference Call Participants Gregory Harrison - Bank of America Yanan Zhu - Wells Fargo Harshita Polishetty - Barcl ...

Sangam Pioneering the Future of Genomic Medicines August 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, CAR-Treg and oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 _______ ...

Sangam Pioneering the Future of Genomic Medicines May 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-T ...

Sangam Pioneering the Future of Genomic Medicines May 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-T ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Conference Call Participants Yanan Zhu - Wells Fargo Nicole Germino - Truist Securities Luca Issi - RBC Capital Kelly O'Brien - Stifel Gregory Harrison - Ban ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR For the transition period from to Commission file number 000-30171 ________________________________________________ SANGAMO THERAPEUTICS, INC. (Exact name of regist ...

Sangam Pioneering the Future of Genomic Medicines February 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Aron Feingold - Head of Corporate Communications Sandy Macrae - CEO Mark McClung - COO Prathyusha Duraibabu - CFO Jason Fontenot - Chief Scientific Officer Rob Schott - Head of Development Bettina Cockroft - Chief Medical Officer Conference Call Participants Nicole Germino - Truist Securities Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Luca Issi - RBC Capital Aspen Mori - Bank o ...